Parental risk factors for fever in their children 7–10 days after the first dose of measles-containing vaccines

References

• Klein NP, Fireman B, Yih WK, Lewis E, Kulldorff M, Ray P, Baxter R, Hambidge S, Nordin J, Naleway A, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–8. doi:10.1542/peds.2010-0665.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, Jackson LA, Nordin J, Lieu T, Belongia EA, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809–14. doi:10.1542/peds.2011-3198.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, Belongia EA, Yih WK, Nordin JD, Hechter RC, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015;135(2):e321–9. doi:10.1542/peds.2014-1822.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013;167(12):1111–17. doi:10.1001/jamapediatrics.2013.2745.
   PubMed Web of Science ®Google Scholar
• Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645–50. doi:10.1016/j.vaccine.2013.12.011.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656–61. doi:10.1016/j.vaccine.2009.05.056.
   PubMed Web of Science ®Google Scholar
• Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, Melbye M, Olsen J. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004;292(3):351–57. doi:10.1001/jama.292.3.351.
   PubMed Web of Science ®Google Scholar
• Carazo Perez S, Bureau A, De Serres G. Post-immunisation fever and the antibody response to measles-containing vaccines. Epidemiol Infect. 2018;146(12):1584–92. doi:10.1017/S0950268818001474.
   PubMed Web of Science ®Google Scholar
• Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: causes, consequences, and a call to action. Am J Prev Med. 2015;49(6 Suppl 4):S391–8. doi:10.1016/j.amepre.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Williams SE. What are the factors that contribute to parental vaccine-hesitancy and what can we do about it? Hum Vaccin Immunother. 2014;10(9):2584–96. doi:10.4161/hv.28596.
   PubMed Web of Science ®Google Scholar
• Saada A, Lieu TA, Morain SR, Zikmund-Fisher BJ, Wittenberg E. Parents’ choices and rationales for alternative vaccination schedules: a qualitative study. Clin Pediatr (Phila). 2015;54(3):236–43. doi:10.1177/0009922814548838.
   PubMed Web of Science ®Google Scholar
• Klein NP, Lewis E, McDonald J, Fireman B, Naleway A, Glanz J, Jackson LA, Donahue JG, Jacobsen SJ, Weintraub E, et al. Risk factors and familial clustering for fever 7–10days after the first dose of measles vaccines. Vaccine. 2017;35(12):1615–21. doi:10.1016/j.vaccine.2017.02.013.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Tseng HF, Liu AL, Qian L, Sy LS, Hechter RC, Marcy SM, Jacobsen SJ. Exploring the risk factors for vaccine-associated and non-vaccine associated febrile seizures in a large pediatric cohort. Vaccine. 2014;32(22):2574–81. doi:10.1016/j.vaccine.2014.03.044.
   PubMed Web of Science ®Google Scholar
• Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, Huang F, Eitson JL, Hollegaard MV, Svanstrom H, Vestergaard M, et al. Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet. 2014;46(12):1274–82. doi:10.1038/ng.3129.
   PubMed Web of Science ®Google Scholar
• Gordon N How does the adult Kaiser Permanente membership in Northern California compare with the larger community? 2006.
   Google Scholar
• Brunell PA, Weigle K, Murphy MD, Shehab Z, Cobb E. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA. 1983;250(11):1409–12. doi:10.1001/jama.1983.03340110023025.
   PubMed Web of Science ®Google Scholar
• Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. Twin studies of immunogenicity–determining the genetic contribution to vaccine failure. Vaccine. 2001;19(17–19):2434–39. doi:10.1016/s0264-410x(00)00468-0.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis. 2006;193(5):655–63. doi:10.1086/500144.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine. 2007;25(16):3090–100. doi:10.1016/j.vaccine.2007.01.020.
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2(5):205–14. doi:10.4161/hv.2.5.3246.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Poland GA, Cunningham JM, Jacobson RM, Ovsyannikova IG, Vierkant RA, Wu Y, Pankratz VS. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J Allergy Clin Immunol. 2007;120(3):666–72. doi:10.1016/j.jaci.2007.04.036.
   PubMed Web of Science ®Google Scholar
• Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Pankratz VS, Jacobson RM, Poland GA. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine. 2008;26(14):1731–36. doi:10.1016/j.vaccine.2008.01.017.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Richmond P, Khoo SK, Zhang G, Yerkovich ST, Le Souef PN, Hayden CM. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine. 2011;29(33):5407–13. doi:10.1016/j.vaccine.2011.05.068.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Hayden CM, Khoo SK, Zhang G, Le Souef PN, Richmond P. CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. Clin Vaccine Immunol. 2012;19(5):704–10. doi:10.1128/CVI.05652-11.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Yerkovich ST, Khoo SK, Zhang G, Upham J, Le Souef PN, Richmond P, Hayden CM. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics. 2012;64(3):219–28. doi:10.1007/s00251-011-0574-0.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Yerkovich ST, Khoo SK, Zhang G, Upham J, Le Souef PN, Richmond P, Hayden CM. TLR3 and RIG-I gene variants: associations with functional effects on receptor expression and responses to measles virus and vaccine in vaccinated infants. Hum Immunol. 2012;73(6):677–85. doi:10.1016/j.humimm.2012.03.004.
   PubMed Web of Science ®Google Scholar
• Clifford HD, Hayden CM, Khoo SK, Naniche D, Mandomando IM, Zhang G, Richmond P, Le Souef PN. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine. 2012;30(43):6180–85. doi:10.1016/j.vaccine.2012.07.063.
   PubMed Web of Science ®Google Scholar